NPC's new white paper, Regulatory Barriers Impair Alignment of Biopharmaceutical Price and Value, highlights the challenges biopharmaceutical manufacturers and payers face when developing value-based contracts.

In NPC President Dan Leonard's column in Chain Drug Review, he explores the mismatch between the savings pharmacy benefit managers (PBMs) boast about and the pinch patients are feeling in their pockets, as well as the disconnect between the role employers believe their PBMs play in managing prescription drug benefits and employers’ perceptions of the overall value they receive from their PBMs.

Join NPC at the International Society for Pharmacoeconomics and Outcomes Research’s (ISPOR) 23rd Annual International Meeting in Baltimore, Maryland, on May 19-23. NPC and its research staff will host an exhibition table and participate in issue panels, a roundtable, a symposium and several poster presentations.